% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Yousefi:272867,
author = {Yousefi, Elham and Gewily, Mohamed and König, Franz and
Höglinger, Günter and Hopfner, Franziska and Karlsson,
Mats O and Ristl, Robin and Zehetmayer, Sonja and Posch,
Martin},
title = {{E}fficiency of multivariate tests in trials in progressive
supranuclear palsy.},
journal = {Scientific reports},
volume = {14},
number = {1},
issn = {2045-2322},
address = {[London]},
publisher = {Macmillan Publishers Limited, part of Springer Nature},
reportid = {DZNE-2024-01284},
pages = {25581},
year = {2024},
abstract = {Measuring disease progression in clinical trials for
testing novel treatments for multifaceted diseases as
progressive supranuclear palsy (PSP), remains challenging.
In this study we assess a range of statistical approaches to
compare outcomes as measured by the items of the progressive
supranuclear palsy rating scale (PSPRS). We consider several
statistical approaches, including sum scores, a modified
PSPRS rating scale that had been recommended by FDA in a
pre-IND meeting, multivariate tests, and analysis approaches
based on multiple comparisons of the individual items. In
addition, we propose two novel approaches which measure
disease status based on Item Response Theory models. We
assess the performance of these tests under various
scenarios in an extensive simulation study and illustrate
their use with a re-analysis of the ABBV-8E12 clinical
trial. Furthermore, we discuss the impact of the
FDA-recommended scoring of item scores on the power of the
statistical tests. We find that classical approaches as the
PSPRS sum score demonstrate moderate to high power when
treatment effects are consistent across the individual
items. The tests based on Item Response Theory (IRT) models
yield the highest power when the simulated data are
generated from an IRT model. The multiple testing based
approaches have a higher power in settings where the
treatment effect is limited to certain domains or items. The
study demonstrates that there is no one-size-fits-all
testing procedure for evaluating treatment effects using
PSPRS items; the optimal method varies based on the specific
effect size patterns. The efficiency of the PSPRS sum score,
while generally robust and straightforward to apply, varies
depending on the specific patterns of effect sizes
encountered and more powerful alternatives are available in
specific settings. These findings can have important
implications for the design of future clinical trials in PSP
and similar multifaceted diseases.},
keywords = {Supranuclear Palsy, Progressive: diagnosis / Humans /
Multivariate Analysis / Clinical Trials as Topic / Disease
Progression / Clinical trials (Other) / Item response theory
(Other) / Multiple endpoints (Other) / Multivariate tests
(Other) / Progressive supranuclear palsy (Other) /
Simulation study (Other)},
cin = {Clinical Research (Munich) / AG Höglinger},
ddc = {600},
cid = {I:(DE-2719)1111015 / I:(DE-2719)1110002},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pmc = {pmc:PMC11514033},
pubmed = {pmid:39462124},
doi = {10.1038/s41598-024-76668-4},
url = {https://pub.dzne.de/record/272867},
}